MASTER SERVICES AGREEMENTMaster Services Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations
This Master Services Agreement (the “Contract”) is agreed to as of July 24, 2002, by and between Inveresk Clinical Research Limited and Inveresk Research International Limited (hereinafter referred to collectively as “Inveresk”) and Salus Pharma, Inc., a Delaware corporation (hereinafter referred to as “the Sponsor”). Sponsor may from time to time issue one or more Project Assignments to Inveresk (“Project Assignment”). Each Project Assignment will include a study protocol (the “Protocol”) applicable thereto. Inveresk will not begin to render services under the Contract unless and until Sponsor issues a Project Assignment for such services (each set of ordered services being a “Project”). Subject to the terms of this Contract, Inveresk will render the services set forth in Project Assignment(s) accepted by Inveresk in accordance with the applicable Protocol and by the completion dates set forth therein.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH TECHNOLOGY LICENSE CONTRACTCorus Pharma Inc • September 15th, 2004 • Pharmaceutical preparations • Minnesota
SERVICES AGREEMENTServices Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • England
This Services Agreement (the “Contract”) is agreed to as of July 1, 2003 (the “Effective Date”) by and between Inveresk Research International Limited with offices at Tranent, EH33 2NE, Scotland, United Kingdom and its Affiliates (hereinafter referred to as “Inveresk”) and Abaris Pharma, Inc., a Delaware corporation with offices at 2025 First Avenue, Suite 800, Seattle, WA 98121 (hereinafter referred to as the “Sponsor”).
SETTLEMENT AGREEMENT AND GENERAL RELEASESettlement Agreement and General Release • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Washington
SETTLEMENT AGREEMENT AND GENERAL RELEASE, dated September 12, 2002, by and among Corus Pharma, Inc., a Delaware corporation (together with its wholly owned subsidiaries, “Corus”), A. Bruce Montgomery, M.D., an individual (“Montgomery”), Jonathan P. Mow, an individual (“Mow”), Bio-Genetic Ventures, Inc., a Washington corporation (“BGV”) and Peter N. Allison, an individual (“Allison”). Corus, Montgomery, Mow, BGV and Allison are sometimes referred to herein together as the “Parties” and individually as a “Party.”
PHARMACEUTICAL SUPPLY AGREEMENTSupply Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Washington
This Agreement is made as of the date it is signed by both parties (the “Effective Date”), by and between Corus Pharma Inc., a Delaware corporation, with its corporate offices at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States of America (“Corus”), and Euticals SpA, doing business at Via Emilia, 99, Frazione San Grato, Lodi (LO) 26900, Italy (“Euticals”).
DEVELOPMENT AGREEMENT BETWEEN ABARIS PHARMA, INC. AND PARI GMBHDevelopment Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Delaware
This Development Agreement (“Agreement”) effective as of April 3, 2003 (the “Effective Date”), is between PARI GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Abaris Pharma, Inc., a Delaware corporation with a principal place of business at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States (“ABARIS”), a wholly owned subsidiary of Corus Pharma, Inc., a Delaware corporation (“Corus”).
DEVELOPMENT AGREEMENT BETWEEN SALUS PHARMA, INC. AND PARI GMBHDevelopment Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Delaware
This Development Agreement (“Agreement”) effective as of February 20, 2002 (the “Effective Date”), is between PARI GmbH, a German corporation with a principal place of business at Moosstrasse 9, D-82319 Starnberg, Germany (“PARI”) and Salus Pharma, Inc., a Delaware corporation with a principal place of business at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States (“SALUS”), a wholly owned subsidiary of Corus Pharma, Inc., a Delaware corporation (“Corus”).
